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Abstract
Eosinophilic esophagitis is a newer disease entity that has been diagnosed with increasing frequency
over the past 10 years. Patients present with a variety of symptoms including vomiting, failure to
thrive, abdominal pain, dysphagia, and/or food impaction depending on the age of the patient. The
diagnosis is confirmed by endoscopy with eosinophilic inflammation localized to the oesophagus, an
area typically void of eosinophils.
Introduction and context
Eosinophilic esophagitis (EE) is a disease entity that has
been diagnosed with increasing frequency. The first
reported case of EE was in 1977 in an adult patient with
food allergies, gastroesophageal reflux disease (GERD)
symptoms, and esophageal eosinophilia [1]. The defini-
tive link between food allergies and EE was shown by
Dr Kelly and colleagues in 1995 [2], when they described
10 patients with isolated esophageal eosinophilia
unresponsive to acid blockade who improved with an
elemental formula. In fact, eight had complete normal-
ization of esophageal eosinophilia after 6 weeks. Their
findings introduced the role of food allergy in EE [2].
Since the mid-nineties, there has been a dramatic rise in
the number of patients diagnosed with EE. EE has now
been reported in every continent except for Africa,
including every state in the United States and most of
Western Europe. Several reports have suggested that the
prevalence of EE has increased in both pediatric and
adult patients by 18- to 35-fold in the past 20 years [3-6].
What is the general approach to management of
eosinophilic esophagitis?
Management of EE involves elimination/control of eosi-
nophils with either medications or diet. Medical treatment
involves treating the symptoms but not the cause of the
disease. It is important to note that there are no current
approved medications for the treatment of EE, however,
the use of ‘topical’ corticosteroids has been shown to be
successful. The patients typically swallow inhaled corticos-
teroids used for asthma in moderate to high doses (given
without use of spacer and avoiding foods/liquids for
30 minutes). The goal of this therapy is to deposit steroids
in the esophagus leading to apoptosis of the eosinophils
and reduction of symptoms. These methods have been
shown to have a varying rate of success. Konikoff et al.[ 7 ]
completed a randomized double-blind placebo-controlled
trial of 36 pediatric patients with EE who either refused
or failed dietary modification. They reported improved
control of symptoms and less eosinophils per high power
field (eosinophils/HPF) in biopsy in 50% of the patients.
The success rate was 50% compared to an 80-90%
success rate in the open-label trials with fluticasone or
budesonide [8,9].
Cromolyn, montelukast (a leukotriene receptor antago-
nist), and omalizumab (an anti-IgE antibody), did not
show any histological improvement in open-label
clinical trials [5,10,11]. At this point, these drugs cannot
be recommended for EE. A recent open label trial of
mepolizumab (an anti-interleukin (IL)-5 antibody)
showed a significant improvement in four patients,
with biopsy improving from 150 to 40 eosinophils/HPF;
however, this was still well above the normal level of 0
eosinophils/HPF [12].
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A second approach is to treat the cause of EE by
eliminating the appropriate food. An elemental diet
has been successful in both pediatric and adult patients,
with success rates surpassing 95% [5,13]. However, due
to the poor palatability of these formulas, it is difficult
for patients to remain on them. A more directed
approach to eliminating the particular food antigen is
possible; two possible ways to remove the food antigen
include removing the most common food allergens or
removing the allergens based on allergy testing. The first
method has been primarily studied by Kagalwalla et al.
[14] in pediatric patients and by Gonsalves in adults (N
Gonsalves, personal communication). They found that a
‘six-food’ elimination diet [no milk, soy, egg, wheat,
seafood (fish and shellfish), and peanuts (peanuts and
tree nuts)] led to a significant reduction of esophageal
eosinophilia. In their pediatric trial, Kagalwalla et al. [14]
started 35 children on the ‘six-food’ elimination diet;
74% of the children had resolution (<10 eosinophils/
HPF) on this diet. In adult trials, the success rate is
reported to be 50% with the elimination diet and
90-95% for the elemental diet (N Gonsalves, personal
communication).
The alternative dietary approach is to remove foods
based on allergy testing. Three standard methods are
used for food testing: prick skin testing, in vitro specific
IgE assays and atopy patch tests. In a study on children,
diets based on positive specific IgE assays had a
response rate near 0% when foods were eliminated
based purely on the in vitro specific IgE assay results
[15]. In the same study, the prick skin test had only a
slightly better success rate of about 50%. This strongly
suggests that the food allergy in EE is not strictly IgE
mediated, consistent with the results with omalizumab.
Based on this finding, we started to use atopy patch
testing for EE [16]. Atopy patch testing is designed to
look for non-IgE-mediated food reactions, presumably
T cell-mediated. We have found that the combination of
both the prick skin and atopy patch tests, looking for
both IgE- and non-IgE-mediated disease, has been
highly successful in the treatment of EE. A food that
was negative on both the prick skin and atopy patch
tests was unlikely to cause EE, with a predictive value of
90% or more for all foods except milk [17]. Addition-
ally, the combination of the skin prick and atopy patch
tests resulted in resolution of EE symptoms and
normalization of biopsies in 80% of patients [17-19].
What is the prognosis?
EE is a chronic disorder. If any treatment, medical or
dietary, is stopped, the symptoms return and esophageal
eosinophilia reoccurs with very rare exceptions.
Longitudinal studies in adults over a 12 year period
have not shown resolution [20].
Recent advances
One of the major advances in the past 2 years was
the First International Gastrointestinal Eosinophil
Research Symposium (FIGERS), a consensus meeting
of allergists, gastroenterologists, and pathologists that
developed clinical recommendations for the diagnosis
and treatment of EE [21]. This group defined EE as a
‘primary clinicopathological disorder of the esophagus’
with diagnosis made by esophageal biopsy with a
finding of ≥15 eosinophils/HPF in one or more
specimens. The report emphasized that gastroesopha-
geal reflux must be aggressively managed prior to
endoscopy with a high dose proton pump inhibitor or
the patient must have evidence of normal distal
esophageal pH as detected by pH probe; this was
based on a case report by Ngo and colleagues [22]
describing three patients whose esophageal eosinophil
count of up to 52 eosinophils/HPF resolved with reflux
medications. Besides gastroesophageal reflux, clini-
cians must keep in mind that esophageal eosinophils
can be seen in other disease entities, including
eosinophilic gastroenteritis (increased eosinophils
throughout the gastrointestinal tract), Crohn’sd i s e a s e ,
collagen vascular disease, hypereosinophilic syndrome,
and drug-associated diseases, and are occasionally
associated with infections.
Additional recent studies have indicated that EE is a
chronic disease, with less than 10% of patients out-
growing it [10,23,24]. The relationship was confirmed in
studies in both adults and children, approximately 75%
of whom had other atopic diseases (allergic rhinitis,
asthma or atopic dermatitis) [25,26] and associations
with celiac disease [27-30] and tracheoesophageal
fistula [31].
Recent studies have confirmed that symptoms of EE
vary by age. Young infants and toddlers typically
present with GERD or failure to thrive due to the
assumed pain associated with eating. School-age
children typically present with abdominal pain or
persistent GERD symptoms. The most common symp-
toms in adolescents and adults include dysphagia and
food impaction [3,21,24]. These symptoms are more
unusual and should immediately suggest the possibility
of EE. These patients were all diagnosed at an early age
and were treated aggressively through avoidance of
allergens. Because the symptoms of EE do not correlate
with endoscopy and histological findings, it is impor-
tant to use endoscopy for diagnosing and following
patients with EE [32].
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tories have made advances in determining the potential
mechanism of EE, showing that IL-13 and fibroblast
growth factor-9 have important roles in the proliferative
responses in the esophagus [33-36]. Straumann et al. [37]
examined the use of infliximab (an anti-tumor necrosis
factor-a antibody) in treating EE, but it had no effect on
histological findings.
Implications for clinical practice
T h em o s tr e c e n ts t u d i e ss u g g e s tt h e r ei sac e r t a i n
phenotype that should be examined carefully for EE.
The stereotypical patient is a male Caucasian with classic
symptoms (dysphagia or food impaction in adolescents
and adults; abdominal pain in school-age children;
GERD symptoms in young children). Also, the lack of
correlation of symptoms with endoscopy findings
indicates the importance of using endoscopy for
diagnosing and following patients with EE. Management
of this disease is primarily through diet as foods are
causative in more than 90% of adults and children.
Medical therapies are being developed for patients with
restrictive and socially difficult diets.
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